|

Expanding Treatment Horizons: CIRT’s Potential for Mesothelioma Patients

ByHolly Zink
Expanding Treatment Horizons: CIRT's Potential for Mesothelioma Patients

When it comes to treating early-stage cancer, surgery is often the recommended approach. But did you know that some patients choose a different option – radiotherapy? In recent years, a special type of radiotherapy called Carbon-ion radiotherapy (CIRT) has become popular, and a study from Japan has shown how it can help people with early-stage lung cancer. CIRT also has treatment applications in mesothelioma.

CIRT: A Different Kind of Treatment

Carbon-ion radiotherapy, or CIRT, is a unique way to treat cancer using special particles called carbon ions instead of X-rays. This treatment has several advantages, making it an attractive choice for people who don’t want surgery. CIRT is known for its ability to control cancer locally while causing fewer severe side effects. It’s becoming more widely available worldwide, but Japan leads the way with the most facilities offering this treatment.

In 2016, Japan started a big study to learn more about the effects of CIRT for lung cancer. They involved all hospitals in Japan that offered CIRT for lung cancer treatment. The data collected from this study gives us valuable information about how well CIRT works for people with early-stage lung cancer. And it gives hope to mesothelioma patients.

What the Study Found

The study looked at patients who received CIRT in Japan between 2016 and 2018, and here are the important things it discovered:

Who Were the Patients? Most of the patients in the study (86%) had stage IA lung cancer, and the rest (14%) had stage IB lung cancer. Some patients were diagnosed based on their symptoms without having a biopsy. Almost all the tumors (97%) were found on the outer edges of the lungs.

How Well Did They Do? The study showed that patients who got CIRT had good results over a 5-year period. Their overall survival rate was 81.8%, their cause-specific survival rate was 91.2%, their progression-free survival rate was 65.9%, and they had a high local control rate of 95.8%. This means that CIRT helped many patients live longer and better.

Factors That Matter: The study also found that a person’s age was important for overall survival. For progression-free survival, age and a measurement called consolidation/tumor ratio played a role. This information can help doctors choose the best treatment for their patients.

Safe Treatment: The study showed that CIRT is a safe treatment option. There were no severe side effects (grade 4 or higher), and only one patient had a grade 3 radiation-related lung problem.

Real-World Data Reveals Success of CIRT

To sum it up, the study tells us that CIRT can be a great way to treat early-stage lung cancer. It’s a treatment option with good outcomes and low side effects. For patients who can’t have surgery or prefer radiotherapy, CIRT is a positive choice that can help them live longer and better.

As researchers continue to explore new ways to treat cancer, it’s important to consider all the options. Carbon-ion radiotherapy is one of those options that looks promising, offering hope and a different choice for patients and their doctors.

Source

Kubo, Nobuteru, Hiroaki Suefuji, Mio Nakajima, Sunao Tokumaru, Naoko Okano, Daisaku Yoshida, Osamu Suzuki, et al. “Five-Year Survival Outcomes after Carbon-Ion Radiotherapy for Operable Stage I Non-Small Cell Lung Cancer: A Japanese National Registry Study (J-CROS-LUNG).” Journal of Thoracic Oncology 0, no. 0 (November 1, 2023). https://doi.org/10.1016/j.jtho.2023.10.016.

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…